Cardiogenesis Transmyocardial Revascularization Registry (ANGINA RELIEF)
The objectives of the registry are as follows:
- Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System;
- Further define the disease characteristics of the population being treated;
- Examine transmyocardial revascularization (TMR) usage characteristics and 30-day outcomes;
- Further assess the 30-day postoperative risk factors for adverse events. To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers.
Class IV Angina
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Target Follow-Up Duration:||30 Days|
|Official Title:||A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction|
- All cause mortality [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- Major adverse cardiovascular events (MACE) rate, defined as the incidence of cardiac-related death, myocardial infarction (Q-wave and non Q-wave), congestive heart failure, cerebrovascular accident, and serious arrhythmia [ Time Frame: 30 days ] [ Designated as safety issue: No ]
- Angina class [ Time Frame: 30 days ] [ Designated as safety issue: No ]
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
The objectives of this patient registry, which collects data on the Cardiogenesis Laser System, include: provide further information on the disease characteristics of the population being treated, examine TMR usage characteristics, monitor 30-day postoperative mortality and MACE rates, and assess preoperative and operative risk factors for adverse events.
To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers. Patient consent indicates approval to allow collection of their confidential data; nonetheless, their identity will not be disclosed in any publication of this study.
The primary endpoint to be assessed in this study is:
• All-cause 30-day mortality
Additional endpoints to be assessed in this study are:
• Major adverse cardiovascular events (MACE) rate, defined as the incidence of cardiac-related death, myocardial infarction (Q-wave and non Q-wave), congestive heart failure, cerebrovascular accident, and serious arrhythmia in the 30-day postoperative period.
The definitions for these events are as follows:
Cardiac-related death: any death that is not clearly attributable to a non-cardiac cause and includes death due to any of the following: acute myocardial infarction, heart failure, cardiogenic shock, pulmonary edema, cardiac tamponade, arrhythmia, or post-procedural complications (i.e., bleeding).
Q-wave myocardial infarction: the appearance of new Q waves of 40 or more milliseconds in 2 or more contiguous leads and elevation of CK-MB.
Non Q-wave myocardial infarction: the elevation of total CK more than twice normal with elevated CK-MB.
Congestive heart failure: Symptoms of pulmonary vascular congestion or a low output state that is due to left ventricular failure and is new in onset or results in re-hospitalization.
Cerebrovascular accident: Any sudden development of neurological deficits due to vascular lesions of the brain such as hemorrhage, embolism, or thrombosis that persists for > 24 hours.
Serious arrhythmia: Supraventricular or ventricular arrhythmias that require sustained intravenous pharmacologic treatment, temporary or permanent pacing, or immediate electrical cardioversion or defibrillation. Arrhythmias resulting in syncope, myocardial ischemia, or death are also classified as serious.
Any other serious operative complications related to the procedure: example: major bleeding requiring transfusion.
Each contributing site is required to complete the Enrollment Failure Log Form for all patients undergoing TMR, but not enrolled into the registry due to inclusion/exclusion criteria failure or did not consent for registry participation. If the decision to perform TMR is done intra-operatively, the patient will be approached for participation in the registry after the procedure. No data should be collected prior to patient consent to take part in the registry.
All data collected must be supported by source documents found at the site. Patient medical records, hospital charts, operative reports, laboratory and diagnostic testing results, office visits, source document worksheets as supplied by the Sponsor, etc. will be utilized for collection of relevant data. All data is subject to 100% source document review by Sponsor personnel and/or a representative of the Sponsor at Sponsor's discretion.
|Contact: Scott Capps, MSfirstname.lastname@example.org|
|United States, Arizona|
|University of Arizona||Recruiting|
|Tuscon, Arizona, United States, 85722|
|Principal Investigator: Robert Poston, MD|
|United States, California|
|Advanced Cardiothoracic Surgery Medical Group||Recruiting|
|Los Angeles, California, United States, 90017|
|Principal Investigator: Ali Gheissari, MD|
|Joseph W. Wilson, MD, Inc.||Recruiting|
|Rancho Mirage, California, United States, 92270|
|Principal Investigator: Joseph W. Wilson, MD|
|United States, Florida|
|Broward Health Medical Center||Recruiting|
|Ft. Lauderdale, Florida, United States, 33316|
|Principal Investigator: Frank Catinella, MD|
|Coastal Cardiovascular and Thoracic Associates, PA||Recruiting|
|Ormond Beach, Florida, United States, 32174|
|Principal Investigator: William H Johnson, MD|
|United States, Georgia|
|Georgia Health Sciences University Research Institute, Inc.||Recruiting|
|Augusta, Georgia, United States, 30912-|
|Principal Investigator: Vinayak Kamath, MD|
|United States, Missouri|
|Saint Luke's Hospital||Recruiting|
|Kansas City, Missouri, United States, 64111|
|Principal Investigator: Keith Allen, MD|
|United States, New York|
|The Feinstein Institute for Medical Research||Recruiting|
|New York, New York, United States, 10075|
|Principal Investigator: Nirav C Patel, MD|
|United States, Oklahoma|
|Oklahoma Heart Hospital||Recruiting|
|Oklahoma City, Oklahoma, United States, 73120|
|Principal Investigator: John Randolph, MD|
|United States, Tennessee|
|East Tennessee Cardiovascular Surgery Group||Recruiting|
|Knoxville, Tennessee, United States, 37923|
|Principal Investigator: Thomas Pollard, MD|
|Tristar Cardiovascular Surgery||Recruiting|
|Nashville, Tennessee, United States, 37203|
|Principal Investigator: V. Seenu Reddy, MD|
|Study Director:||Scott Capps, MS||CryoLife, Inc.|